Background: Preeclampsia is reported to complicate 2% - 8% of pregnancies globally and is an important cause of maternal and perinatal morbidity and mortality. The aetiology and pathogenesis are still poorly understood and substantial improvement has not been made in the prediction, prevention and treatment of the disease. Objective: To compare the frequency of activated protein C resistance (APC-R) in patients with pre-eclampsia to that of normotensive pregnant women and to determine the correlation between activated protein ratio (APC-ratio) and the severity of pre-eclampsia. Methodology: A cross-sectional study was carried out in 100 pre-eclamptic patients and 100 normotensive pregnant controls. The APC-ratio was determined using the modified activated partial thromboplastin time. Study participants with APC-ratio of less than 2.0 were defined as having APC-R. Data was analyzed using SPSS version 22.0. Results: Mean APC-ratio was significantly lower in pre-eclamptics (2.89 ± 1.70) compared to normotensive pregnant women (3.57 ± 1.06) (p = 0.0008) and the levels were also higher in mild (2.95 ± 1.15) compared to severe pre-eclamptics (2.62 ± 1.14). The frequency of APC-R was 26% among women with pre-eclampsia compared to 4% among normotensive controls (p = 0.000). Among 100 pre-eclamptic women 7 (21.2%) out of 33 with mild pre–eclampsia had APC-R, while 19 (28.4%) out of 67 with severe pre-eclampsia had APC-R. APC-ratio had a significant negative correlation with mean arterial blood pressure (r = −0.324; p = 0.000) and proteinuria (r = −0.379; p = 0.000) among study participants. Conclusion: The frequency of activated protein c resistance is significantly higher in pre-eclamptics compared to normotensive pregnant women and this is more pronounced in those with severe pre-eclampsia compared with those with mild disease. APC-R may therefore be used as a marker of severity in the disease.
References
[1]
Cudihy, D. and Lee, R.V. (2009) The Pathopysiology of Pre-Eclampsia: Current Clinical Concepts. Journal of Obstetrics and Gynaecology, 29, 576-582. https://doi.org/10.1080/01443610903061751
[2]
Winner, N. and Tsasari, S.V. (2008) Latest Developments, Management, and Treatment of Pre-Eclampsia. European Journal of Obstetrics & Gynecology and Reproductive Biology, 37, 5-13.
[3]
Eiland, E., Nzerue, C. and Faulkner, M. (2012) Preeclampsia 2012. Journal of Pregnancy, 2012, Article ID: 586578. https://doi.org/10.1155/2012/586578
[4]
Ghulmiyyah, L. and Sibai, B. (2012) Maternal Mortality from Preeclampsia/Eclampsia. Seminars in Perinatology, 36, 56-59. https://doi.org/10.1053/j.semperi.2011.09.011
[5]
Adeyeye, O.V., Ebubechukwu, N.V., Olanrewaju, D.F., Eniayewun, A.G., Nwuta, C., Effiong, F.B., et al. (2023) Management and Prevention of Pre-Eclampsia in Nigeria. Healthcare, 23, Article 1832. https://doi.org/10.3390/healthcare11131832
[6]
Musa, J., Mohammed, C., Ocheke, A., Kahansim, M., Pam, C. and Daru, P. (2018) Incidence and Risk Factors for Pre-Eclampsia in Jos, Nigeria. African Health Sciences,18, 584-595. https://doi.org/10.4314/ahs.v18i3.16
[7]
Akaba, G.O., Ayang, U.I. and Ekele, B.A. (2021) Prevalence and Materno-Fetal Outcomes of Preeclampsia/Eclampsia among Pregnant Women at a Tertiary Hospital in North-Central Nigeria: A Retrospective Cross-Sectional Study. Clinical Hypertension, 27, Article No. 20. https://doi.org/10.1186/s40885-021-00178-y
[8]
Ekele, B.A. (2009) Use of Magnesium Sulphate to Manage Pre-Eclampsia in Nigeria. Overcoming the Odds. Annals of African Medicine, 8, 73-75. https://doi.org/10.4103/1596-3519.56231
[9]
Kullima, A.A., Kawuwa, M.B., Audu, B.M., Geidam, A.D. and Mairiga, A.G. (2009) Trends in Maternal Mortality in a Tertiary Institution in Northern Nigeria. Annals of African Medicine, 8, 221-224. https://doi.org/10.4103/1596-3519.59575
[10]
Olamijulo, J.A., Olorunfemi, G., Olaleye, O., Ogedengbe, O.K. and Giwa-Osagie, O.F. (2012) Trends in Maternal Mortality at the Lagos University Teaching Hospital, Lagos, Nigeria. Nigerian Quarterly Journal of Hospital Medicine, 22, 72-79.
[11]
Roberts, J.M. and Cooper, D.W. (2001) Pathogenesis and Genetics of Pre-Eclampsia. The Lancet, 357, 53-56. https://doi.org/10.1016/S0140-6736(00)03577-7
[12]
Bisson, C., Dautel, S., Patel, E., Suresh, S., Dauer, P. and Rana, S. (2023) Preeclampsia Pathophysiology and Adverse Outcome during Pregnancy and Postpartum. Frontiers in Medicine, 10, Article 1144170. https://doi.org/10.3389/fmed.2023.1144170
[13]
Ives, C.W., Sinkey, R., Rajapreyar, I., Tita, A.T.N. and Oparil, S. (2020) Preeclampsia Pathophysiology and Clinical Presentation; JACC State-of-the-Art Review. Journal of the American College of Cardiology, 76, 1690-1702. https://doi.org/10.1016/j.jacc.2020.08.014
[14]
Paternoster, D.M., Surico, N., Riboni, F., Gambaro, C., Girolami, A., Milani, M., et al. (2007) Thrombophilia in Pregnancy and Their Role in Preeclampsia. Expert Review of Obstetrics & Gynecology, 2, 663-670. https://doi.org/10.1586/17474108.2.5.663
[15]
Deveer, R., Engin-Ustun, Y., Akbaba, E., Halisdemir, B., Cakar, E., Danismae, N., et al. (2013) Association between Pre-Eclampsia and Inherited Thrombophilias. Fetal and Pediatric Pathology, 32, 213-217. https://doi.org/10.3109/15513815.2012.721475
[16]
Gree, I.A., Aharon, A., Brenner, B. and Gris, J.C. (2014) Coagulation and Plancenta-Mediated Complications. Rambam Maimonides Medical Journal, 5, e0034. https://doi.org/10.5041/RMMJ.10168
[17]
The British Committee for Standards in Haematology (1990) Guidelines for Investigation and Management of Thrombophilia. Journal of Clinical Pathology, 43, 703-709. https://doi.org/10.1136/jcp.43.9.703
[18]
Kupferminc, M.J. (2003) Thrombophilia and Pregnancy. Reproductive Biology and Endocrinology, 1, Article No. 111. https://doi.org/10.1186/1477-7827-1-111
[19]
Khan, S. and Dickerman, J.D. (2006) Hereditary Thrombophilia. Thrombosis Journal, 4, Article No. 15. https://doi.org/10.1186/1477-9560-4-15
[20]
Dawood, F. (2013) Pregnancy and Thrombophilia. Journal of Blood Disorders and Transfusion, 4, Article 1000164. https://doi.org/10.4172/2155-9864.1000164
[21]
Dahlback, B. and Hildebrand, B. (1994) Inherited Resistance to Activated Protein C Is Corrected by Anticoagulant Cofactor Activity Found to be a Property of Factor V. Proceedings of the National Academy of Sciences of the United States of America, 91, 1396-1400. https://doi.org/10.1073/pnas.91.4.1396
[22]
Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R.J., de Ronde, H., et al. (1994) Mutation in Blood Coagulation Factor V Associated with Resistance to Activated Protein C. Nature, 369, 64-67. https://doi.org/10.1038/369064a0
[23]
De Ronde, H. and Bertina, R.M. (1994) Laboratory Diagnosis of APC-Resistance: A Critical Evaluation of the Test and the Development of Diagnostic Criteria. Thrombosis and Haemostasis, 72, 880-886. https://doi.org/10.1055/s-0038-1648978
[24]
Villareal, C., Garcia-Aguirre, G., Hernandez, C., Vega, O., Borbolla, J.R. and Collados, M.T. (2002) Congenital Thrombophilia Associated with Obstetrics Complications. Journal of Thrombosis and Thrombolysis, 14, 163-169. https://doi.org/10.1023/A:1023293114529
[25]
Finan, R.R., Tamim, H., Ameen, G., Sharida, H.E., Rashid, M.M. and Almawi, W.Y. (2002) Prevalence of Factor V G1691A (Factor V-Leiden) and Prothrombin G20210A Gene Mutations in a Recurrent Miscarriage Population. American Journal of Hematology, 71, 300-305. https://doi.org/10.1002/ajh.10223
[26]
Adeyemo, T.A., Adediran, A., Akinbami, A.A. and Akanmu, A.S. (2012) Prevalence of Activated Protein C Resistance (Factor V Leiden) in Lagos, Nigeria. Nigerian Journal of Clinical Practice, 15, 136-141. https://doi.org/10.4103/1119-3077.97287
[27]
Mello, G., Parretti, E., Marozio, L., Pizzi, C., Lojacono, A., Frusca, T., et al. (2005) Thrombophilia Is Significantly Associated with Severe Preeclampsia: Results of a Large Case, Case Control Study. Hypertension, 46, 1270-1274. https://doi.org/10.1161/01.HYP.0000188979.74172.4d
[28]
Paternoster, D.M., Stella, A., Simioni, P., Girolami, A. and Snijders, D. (2002) Activated Protein C in Normal and Pre-Eclamptic Pregnancies. Gynecologic and Obstetric Investigation, 54, 145-149. https://doi.org/10.1159/000067878
[29]
Sedano-Balbas, S., Lyons, M., Cleary, B., Murray, M., Gaffney, G. and Maher, M. (2011) Acquired Activated Protein C Resistance, Thrombophilia and Adverse Pregnancy Outcomes: A Study Performed in an Irish Cohort of Pregnant Women. Journal of Pregnancy, 2011, Article ID: 232840. https://doi.org/10.1155/2011/232840
[30]
Karimi, S., Yavarian, M., Azinfar, A., Rajael, M. and AziziKootenaee, M. (2012) Evaluation the Frequency of Factor V Leiden Mutation in Pregnant Women with Preeclampsia Syndrome in an Iranian Population. Iranian Journal of Reproductive Medicine, 10, 59-66.
[31]
Dudding, T., Heron, J., Thakkinstian, A., Nurk, E., Golding, J., Pembrey, M., et al. (2008) Factor V Leiden Is Associated with Pre-Eclampsia but not with Fetal Growth Restriction: A Genetic Association Study and Meta-Analysis. Journal of Thrombosis and Haemostasis, 6, 1869-1875. https://doi.org/10.1111/j.1538-7836.2008.03134.x
[32]
Lin, J. and August, P. (2005) Genetic Thrombophilia and Pre-Eclampsia: A Meta-Analysis. Obstetrics & Gynecology, 105, 182-189. https://doi.org/10.1097/01.AOG.0000146250.85561.e9
[33]
Kahn, S.R., Platt, R., McNamara, H., Rozen, R., Chen, M.F., Genest Jr., J., et al. (2009) Inherited Thrombophilia and Preeclampsia within a Multicentre Cohort: The Montreal Preeclampsia Study. American Journal of Obstetrics & Gynecology, 200, 151. E1-E9. https://doi.org/10.1016/j.ajog.2008.09.023
[34]
Deveer, R., Engin-Ustun, Y., Akbaba, E., Halisdemir, B., Cakar, E., Danisman, N., et al. (2013) Association between Pre-Eclampsia and Inherited Thrombophilias. Fetal and Pediatric Pathology, 32, 213-217. https://doi.org/10.3109/15513815.2012.721475
[35]
Rodger, M.A., Betancourt, M.T., Clark, P., Lindqvist, P.G., Dizon-Townson, D., Said, J., et al. (2010) The Association between Factor V Leiden and Prothrombin Gene Mutation and Placental Mediated Pregnancy Complications: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. PLOS Medicine, 7, Article 1000292. https://doi.org/10.1371/journal.pmed.1000292
[36]
Hira, B., Pegoraro, R.J., Rom, L. and Moodley, J. (2003) Absence of Factor V Leiden, Thrombomodulin and Prothrombin Gene Variants in Black South African Women with Pre-Eclampsia and Eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology, 110, 327-328. https://doi.org/10.1046/j.1471-0528.2003.01090.x
[37]
Glenn, I.D. (1992) Determining Sample Size. Florida Cooperative Extension Services, Fact Sheet PEOD-6, Institue of Food and Agricultural Sciences, University of Florida.
[38]
Esman, C.T. (1993) Molecular Events That Control the Protein C Anticoagulation Pathway. Thrombosis and Haemostasis, 70, 29-35. https://doi.org/10.1055/s-0038-1646155
[39]
Kosmas, I.P., Taksioni, A. and Ioannidis, J.P. (2003) Association of Leiden Mutation in Factor V Gene with Hypertension in Pregnancy and Pre-Eclampsia. A Meta-Analysis. Journal of Hypertension, 21, 1221-1228. https://doi.org/10.1097/00004872-200307000-00002
[40]
Horstkamp, B.S., Kiess, H., Kramer, J., Henrich, W. and Dudenhausen, J.W. (1999) Activated Protein C Resistance Shows an Association with Pregnancy-Induced Hypertension. Human Reproduction, 14, 3112-3115. https://doi.org/10.1093/humrep/14.12.3112
[41]
Lenz, B., Samardzija, M., Drenjanceviq, D., Zibar, D., Samardzija, M. and Milostic-Srb, A. (2016) The Investigation of Hereditary and Acquired Thrombophilia Risk Factors in the Development of Complications of Pregnancy in Croatian Women. The Journal of Maternal-Fetal & Neonatal Medicine, 29, 264-269. https://doi.org/10.3109/14767058.2014.998189
[42]
Rees, D.C., Cox, M. and Clegg, J.B. (1995) World Distribution of Factor V Leiden. The Lancet, 346, 1133-1134. https://doi.org/10.1016/S0140-6736(95)91803-5
[43]
Nwagha, U.T., Nwagha, U.I., Ibegbulam, O.G., Ocheni, S., Okpala, I., Ezeonu, P.O., et al. (2012) Increased Prevalence of Activated Protein C Resistance during Pregnancy May Implicate Venous Thrombo Embolic Disorders as a Common Cause of Maternal Mortality in Nigeria. Journal of Basic and Clinical Reproductive Sciences, 1, 19-24.
[44]
Matsouka, C.J. (2005) Haemostatic Changes during Pregnancy. HAEMA, 8, S68-S71.
[45]
De Vries, J.I., van Pampus, M.G., Hague, W.M., Bezemer, P.D. and Joosten, J.H. On Behalf of Fruit Investigators (2012) Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Pre-Eclampsia in Women with Inheritable Thrombophilia: The FRUIT-RCT. Journal of Thrombosis and Haemostasis, 10, 64-72. https://doi.org/10.1111/j.1538-7836.2011.04553.x
